Elmiron lawsuit claims allege that long-term use of the bladder drug pentosan polysulfate sodium caused serious eye damage. Thousands of patients developed a condition called pigmentary maculopathy after taking Elmiron for interstitial cystitis. This unique retinal disorder can cause permanent vision loss. The drug’s manufacturer, Janssen Pharmaceuticals (a Johnson & Johnson subsidiary), faces accusations of failing to warn patients and doctors for decades. As of March 2026, hundreds of cases remain pending in federal court. If you took Elmiron and experienced vision problems, you may qualify to seek compensation.
Case Timeline
Last checked: September 03, 2026
What Is the Elmiron Lawsuit About?
| MDL Detail | Current Data |
|---|---|
| MDL Number | MDL-2973 |
| Pending Cases | 286 |
| Presiding Judge | Brian R. Martinotti |
| Federal District | NJ |
| Data Source | U.S. Judicial Panel on Multidistrict Litigation |
| Last Updated | August 03, 2026 |
Elmiron (pentosan polysulfate sodium) is the only FDA-approved oral medication for interstitial cystitis. The FDA approved it in 1996. Millions of patients — mostly women — relied on this drug to manage chronic bladder pain. However, researchers discovered in 2018 that long-term Elmiron use damages the retina. Dr. Nieraj Jain and colleagues published findings linking the drug to pigmentary maculopathy. This condition causes blurred vision, difficulty reading, and trouble adjusting to low light.
The Elmiron lawsuit centers on the manufacturer’s failure to warn. Janssen Pharmaceuticals did not add retinal damage warnings to the drug label until June 2020. That delay left patients exposed for nearly 25 years without knowledge of the risk. Plaintiffs allege that Janssen knew or should have known about the eye damage connection much earlier. As a result, many patients continued taking Elmiron while their vision quietly deteriorated.
The injuries in these cases are often irreversible. Pigmentary maculopathy has no cure. In most cases, the damage may continue progressing even after patients stop taking Elmiron. Many plaintiffs were initially misdiagnosed with age-related macular degeneration. The correct diagnosis only emerged after the medical community recognized this distinct drug-induced condition.
MDL Case Status and Key Facts
| Detail | Information |
|---|---|
| MDL Number | MDL No. 2973 |
| Case Number | 2:20-md-02973 |
| Presiding Judge | U.S. District Judge Brian R. Martinotti |
| Federal District | U.S. District Court, District of New Jersey |
| Pending Cases (March 2026) | Approximately 634 |
| Total Cases Filed | 1,988 |
| Bellwether Trial | Originally scheduled March 2023; canceled — no trial held |
| Defendants | Janssen Pharmaceuticals, Johnson & Johnson, Teva Pharmaceuticals |
The Judicial Panel on Multidistrict Litigation consolidated Elmiron lawsuit cases in New Jersey. The pending case count peaked at roughly 1,911 in early 2024. Since then, confidential settlement activity has reduced that number significantly. By March 2026, only 634 actions remained pending. An additional 246 cases are proceeding in New Jersey and Pennsylvania state courts.
The first bellwether case, Windham v. Janssen Pharmaceuticals, was originally set for January 2023. It was rescheduled to March 2023. However, in April 2023, both sides jointly withdrew all pending motions. No bellwether trial has ever gone to verdict in this Elmiron lawsuit MDL. Special Master Mark Falk has been facilitating settlement conferences between the parties.
Who Qualifies for the Elmiron Lawsuit?
You might be eligible for an Elmiron lawsuit claim if you took the drug and developed vision problems. Typically, qualifying plaintiffs used Elmiron for interstitial cystitis over a period of months or years. Most documented cases of retinal damage involved three or more years of use. However, shorter-duration cases have also been reported. Cumulative dose appears to be a key risk factor.
Qualifying injuries include pigmentary maculopathy, blurred or distorted vision, and difficulty reading. Dark spots in central vision and trouble adjusting to dim lighting also qualify. Some plaintiffs have experienced significant vision loss or legal blindness. For example, a patient who was misdiagnosed with age-related macular degeneration may actually have Elmiron-related maculopathy. An eye examination using OCT imaging and autofluorescence testing can help confirm the diagnosis.
Evidence typically needed includes pharmacy records showing Elmiron prescriptions. Medical records documenting vision changes are also important. An ophthalmologist’s diagnosis of pigmentary maculopathy strengthens a claim considerably. You should consult a licensed attorney to evaluate whether your specific situation meets the requirements for filing.
How to File an Elmiron Lawsuit Claim
Filing an Elmiron lawsuit claim begins with consulting a mass tort attorney experienced in pharmaceutical litigation. Most attorneys offer free case evaluations. They will review your medical history, prescription records, and vision diagnoses. If your case qualifies, your attorney will file on your behalf in the MDL or an appropriate state court. You typically pay nothing upfront because these cases operate on a contingency fee basis.
After filing, you will likely need to complete a Plaintiff Fact Sheet. This document provides detailed information about your Elmiron use, medical treatment, and injuries. Your attorney will help you gather the necessary documentation. In most cases, medical records and pharmacy records are the most critical evidence. Your lawyer may also arrange for an independent ophthalmologic examination.
Statute of limitations deadlines vary by state. Most states apply a discovery rule. This means the clock starts when you knew or should have known that Elmiron caused your eye damage. Since the connection was not publicly recognized until 2018, some plaintiffs may still have time to file. However, acting promptly is essential. Many filing windows are closing as awareness of this litigation grows. Consult an attorney as soon as possible to protect your rights.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
Elmiron Lawsuit Settlement Updates and What to Expect
No formal global settlement has been publicly announced in the Elmiron lawsuit MDL as of early 2026. However, substantial confidential settlement activity is underway. The steady decline in pending cases — from roughly 1,911 to 634 — strongly suggests that hundreds of claims have been individually resolved. In November 2025, Special Master Falk authorized more than $43 million in attorney fees to 30 law firms. He also approved $3 million in expense reimbursements.
Settlement amounts in Elmiron lawsuit cases vary widely based on several factors. The severity of vision loss plays the largest role. Other factors include the duration of Elmiron use, the plaintiff’s age, and the impact on daily life. Legal analysts note that cases involving severe vision impairment or blindness may receive significantly higher compensation than those with mild symptoms. Each case is evaluated individually based on its specific facts.
The timeline for resolution depends on where your case stands in the process. Plaintiffs who have already filed may see resolution within months. New filers should expect the process to take one to three years. Typically, mass tort settlements involve a review period, documentation verification, and a disbursement phase. Your attorney can provide a more specific timeline based on your circumstances.
State-by-State Considerations
State tort reform laws can significantly affect an Elmiron lawsuit claim. Each state has different rules regarding damage caps, expert witness requirements, and statutes of limitations. For example, New Jersey and Pennsylvania have the highest concentration of filed cases due to the MDL location and companion state litigation. States like Virginia apply a two-year statute of limitations from the date of diagnosis. Missouri allows up to five years from the date of injury discovery. Some states impose caps on non-economic damages that may limit total recovery.
Understanding your state’s specific rules is critical. Tort reform measures in states like Texas and Florida may affect how damages are calculated. You can learn more about how your state’s laws apply to mass tort claims on our state-by-state tort reform guide. A licensed attorney in your jurisdiction can explain how local laws affect your potential Elmiron lawsuit claim.
Frequently Asked Questions
Is Elmiron still on the market?
Yes, Elmiron remains available by prescription. The FDA updated its label in 2020 to include warnings about pigmentary maculopathy. The agency now recommends baseline eye exams within six months of starting the drug and periodic monitoring during treatment. Elmiron has not been recalled.
How long do I have to file an Elmiron lawsuit?
Filing deadlines depend on your state’s statute of limitations. Most states allow two to three years from the date you discovered (or should have discovered) the connection between Elmiron and your vision problems. Because this link was not widely known until 2018, some plaintiffs may still qualify. However, you should consult an attorney promptly to determine your specific deadline.
What if my eye doctor diagnosed me with macular degeneration instead of maculopathy?
Many Elmiron patients were initially misdiagnosed with age-related macular degeneration. The two conditions can appear similar on standard eye exams. Specialized testing such as OCT imaging and fundus autofluorescence can distinguish Elmiron-related maculopathy. If you took Elmiron and received an AMD diagnosis, ask your ophthalmologist about retesting. A corrected diagnosis may support your Elmiron lawsuit claim.
Check If You May Qualify
Mass tort eligibility depends on your specific exposure, injuries, and the state where you live. A licensed mass tort attorney can evaluate your situation at no upfront cost — most work on contingency, meaning you pay nothing unless you recover compensation.
Official Sources & Resources
For verified mass tort and MDL information:
- JPML: jpml.uscourts.gov — official MDL statistics and transfer orders
- DOJ: justice.gov — settlement announcements and press releases
- FDA: fda.gov — drug recalls, warning letters, and safety alerts
- CDC: cdc.gov — health condition data and exposure guidelines
- EPA: epa.gov — environmental contamination data
- Cornell LII: law.cornell.edu — plain-English legal definitions
Content last reviewed May 2026. This is general educational information, not legal advice. If you notice outdated information, please contact us.
Related Guides
- All Active MDL Cases
- More in This Category
- Tort Reform by State — 50-State Comparison
- All 50 State Tort Reform Guides
- Mass Tort Explainers
- Demographic Guides
- Mass Tort Tips
- California Tort Reform Guide
- Ohio Tort Reform Guide
- Texas Tort Reform Guide
Attorney Advertising. The information on this page is provided for general informational purposes only and does not constitute legal advice. No attorney-client relationship is created by accessing or using this content. Every case is unique, and results depend on the specific facts and circumstances involved. Past settlement amounts and case outcomes do not guarantee similar results in your case. If you believe you have a legal claim, you should consult with a licensed attorney in your jurisdiction who can evaluate your specific situation.